Telmisartan increases vascular reparative capacity in older HIV-infected adults: a pilot study

References

• Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964–966.10.1126/science.275.5302.964
   PubMed Web of Science ®Google Scholar
• Takahashi T, Kalka C, Masuda H, et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5(4):434–438.
   PubMed Web of Science ®Google Scholar
• Asahara T, Masuda H, Takahashi T, et al. Bone Marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999;85(3):221–228.10.1161/01.RES.85.3.221
   PubMed Web of Science ®Google Scholar
• Werner N, Priller J, Laufs U, et al. Bone Marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol. 2002;22(10):1567–1572.10.1161/01.ATV.0000036417.43987.D8
   PubMed Web of Science ®Google Scholar
• Kuliczkowski W, Derzhko R, Prajs I, Podolak-Dawidziak M, Serebruany VL. Endothelial progenitor cells and left ventricle function in patients with acute myocardial infarction: potential therapeutic considertions. Am J Ther. 2012;19(1):44–50.10.1097/MJT.0b013e3181e0cab3
   PubMed Web of Science ®Google Scholar
• Leone AM, Rutella S, Bonanno G, et al. Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function. Eur Heart J. 2005;26(12):1196–1204.10.1093/eurheartj/ehi164
   PubMed Web of Science ®Google Scholar
• Krankel N, Luscher TF, Landmesser U. “Endothelial progenitor cells” as a therapeutic strategy in cardiovascular disease. Curr Vasc Pharmacol. 2012;10(1):107–124.10.2174/157016112798829832
   PubMed Web of Science ®Google Scholar
• Chironi G, Walch L, Pernollet MG, et al. Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis. 2007;191(1):115–120.10.1016/j.atherosclerosis.2006.02.041
   PubMed Web of Science ®Google Scholar
• Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89(1):E1–e7.10.1161/hh1301.093953
   PubMed Web of Science ®Google Scholar
• Schmidt-Lucke C, Rossig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005;111(22):2981–2987.10.1161/CIRCULATIONAHA.104.504340
   PubMed Web of Science ®Google Scholar
• Fadini GP, Coracina A, Baesso I, et al. Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke. 2006;37(9):2277–2282.10.1161/01.STR.0000236064.19293.79
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999–1007.10.1056/NEJMoa043814
   PubMed Web of Science ®Google Scholar
• Hill JM, Zalos G, Halcox JP, et al. Circulating Endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. 2003;348(7):593–600.10.1056/NEJMoa022287
   PubMed Web of Science ®Google Scholar
• Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med. 2009;17(3):98–103.
   PubMedGoogle Scholar
• Currier JS, Lundgren JD, Carr A, et al. Epidemiological evidence for cardiovascular disease in HIV-Infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008;118(2):e29–e35.10.1161/CIRCULATIONAHA.107.189624
   PubMedGoogle Scholar
• Costiniuk CT, Hibbert BM, Simard T, Ghazawi FM, Angel JB, O’Brien ER. Circulating endothelial progenitor cells in HIV infection: a systematic review. Trends Cardiovasc Med. 2013;23(6):192–200.10.1016/j.tcm.2012.12.002
   PubMed Web of Science ®Google Scholar
• López M, Vispo E, San Román J, et al. Short Communication high risk of endothelial dysfunction in HIV individuals may result from deregulation of circulating endothelial cells and endothelial progenitor cells. AIDS Res Hum Retroviruses. 2012;28(7):656–659.10.1089/aid.2011.0152
   PubMed Web of Science ®Google Scholar
• Teofili L, Iachininoto MG, Capodimonti S, et al. Endothelial progenitor cell trafficking in human immunodeficiency virus-infected persons. AIDS. 2010;24(16):2443–2450.10.1097/QAD.0b013e32833ef79d
   PubMed Web of Science ®Google Scholar
• McNamara LA, Onafuwa-Nuga A, Sebastian NT, Riddell Jt, Bixby D, Collins KL. CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J Infect Dis. 2013;207(12):1807–1816.10.1093/infdis/jit118
   PubMed Web of Science ®Google Scholar
• Bordoni V, Bibas M, Abbate I, et al. Bone marrow CD34+ progenitor cells may harbour HIV-DNA even in successfully treated patients. Clin Microbiol Infect. 2015;21(3):e5–e8.
   PubMed Web of Science ®Google Scholar
• Gómez-Garre D, Estrada V, Ortega-Hernández A, et al. Association of HIV-infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis. J Acquir Immune Defic Syndr. 2012;61(5):545–551.10.1097/QAI.0b013e31826afbfc
   PubMed Web of Science ®Google Scholar
• Carter CC, Onafuwa-Nuga A, McNamara LA, et al. HIV-1 infects multipotent progenitor cells causing cell death and establishing latent cellular reservoirs. Nat Med. 2010;16(4):446–451.10.1038/nm.2109
   PubMed Web of Science ®Google Scholar
• Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et al. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS ONE. 2014;9(3):e90541.10.1371/journal.pone.0090541
   PubMed Web of Science ®Google Scholar
• Bernal E, Verdu JM, Vera F, et al. Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc. J Int AIDS Soc. 2014;17(4 Suppl 3):19726.
   PubMed Web of Science ®Google Scholar
• Wago T, Yoshimoto T, Akaza I, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. Hypertens Res Official J Jpn Soc Hypertens. 2010;33(8):796–801.10.1038/hr.2010.107
   PubMed Web of Science ®Google Scholar
• Perl S, Schmölzer I, Sourij H, et al. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance. Int J Cardiology. 2010;139(3):289–296.10.1016/j.ijcard.2008.10.048
   PubMed Web of Science ®Google Scholar
• Benndorf RA, Appel D, Maas R, Schwedhelm E, Wenzel UO, Böger RH. Telmisartan Improves endothelial function in patients with essential hypertension. J Cardiovasc Pharmacol. 2007;50(4):367–371.10.1097/FJC.0b013e31811dfbe7
   PubMed Web of Science ®Google Scholar
• Jung AD, Kim W, Park SH, et al. The effect of telmisartan on endothelial function and arterial stiffness in patients with essential hypertension. Korean Circulation J. 2009;39(5):180–184.10.4070/kcj.2009.39.5.180
   PubMedGoogle Scholar
• Bahlmann FH, de Groot K, Mueller O, Hertel B, Haller H, Fliser D. Stimulation of Endothelial progenitor cells: a new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension. 2005;45(4):526–529.10.1161/01.HYP.0000159191.98140.89
   PubMed Web of Science ®Google Scholar
• Pelliccia F, Pasceri V, Cianfrocca C, et al. Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis. 2010;210(2):510–515.10.1016/j.atherosclerosis.2009.12.005
   PubMed Web of Science ®Google Scholar
• Endtmann C, Ebrahimian T, Czech T, et al. Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration. Hypertension. 2011;58(3):394–403.10.1161/HYPERTENSIONAHA.110.169193
   PubMed Web of Science ®Google Scholar
• Fadini GP, Losordo D, Dimmeler S. Critical Reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110(4):624–637.10.1161/CIRCRESAHA.111.243386
   PubMed Web of Science ®Google Scholar
• Blann AD, Woywodt A, Bertolini F, et al. Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost. 2005;93(2):228–235.
   PubMed Web of Science ®Google Scholar
• Calò LA, Dal Maso L, Pagnin E, et al. Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients. J Hypertens. 2014;32(1):193–199.10.1097/HJH.0b013e32836522c3
   PubMed Web of Science ®Google Scholar
• Tan H, Li X, Chen W, et al. Effects of losartan on the mobilization of endothelial progenitor cells and improvement of endothelial function. Ann Clin Lab Sci. 2013;43(4):402–406.
   PubMed Web of Science ®Google Scholar
• Li H, Liu Q, Wang N, Xu J. Correlation of different NADPH oxidase homologues with late endothelial progenitor cell senescence induced by angiotensin II: effect of telmisartan. Intern Med. 2011;50(16):1631–1642.10.2169/internalmedicine.50.5250
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Maiorino MI, et al. Circulating CD34+KDR+ Endothelial progenitor cells correlate with erectile function and endothelial function in overweight men. J Sex Med. 2009;6(1):107–114.10.1111/j.1743-6109.2008.01042.x
   PubMed Web of Science ®Google Scholar
• Wang CH, Ciliberti N, Li SH, et al. Rosiglitazone facilitates angiogenic progenitor cell differentiation toward endothelial lineage: a new paradigm in glitazone pleiotropy. Circulation. 2004;109(11):1392–1400.10.1161/01.CIR.0000123231.49594.21
   PubMed Web of Science ®Google Scholar
• Amano Y, Yamaguchi T, Ohno K, et al. Structural basis for telmisartan-mediated partial activation of PPAR gamma. Hypertens Res. 2012;35(7):715–719.10.1038/hr.2012.17
   PubMed Web of Science ®Google Scholar
• Spigoni V, Picconi A, Cito M, et al. Pioglitazone improves in vitro viability and function of endothelial progenitor cells from individuals with impaired glucose tolerance. PLoS ONE. 2012;7(11):e48283.10.1371/journal.pone.0048283
   PubMed Web of Science ®Google Scholar
• Esposito K, Maiorino MI, Di Palo C, et al. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes–a randomized controlled trial. Diabetes Obes Metab. 2011;13(5):439–445.10.1111/dom.2011.13.issue-5
   PubMed Web of Science ®Google Scholar
• Cao Z, Yang Y, Hua X, et al. Telmisartan promotes proliferation and differentiation of endothelial progenitor cells via activation of Akt. Chin Med J (Engl). 2014;127(1):109–113.
   PubMed Web of Science ®Google Scholar
• Honda A, Matsuura K, Fukushima N, Tsurumi Y, Kasanuki H, Hagiwara N. Telmisartan induces proliferation of human endothelial progenitor cells via PPARγ-dependent PI3K/Akt pathway. Atherosclerosis. 2009;205(2):376–384.10.1016/j.atherosclerosis.2008.12.036
   PubMed Web of Science ®Google Scholar
• Esplugues JV, De Pablo C, Collado-Díaz V, Hernández C, Orden S, Álvarez Ángeles. Interference with purinergic signalling: an explanation for the cardiovascular effect of abacavir? AIDS. 2016;30(9):1341–1351.10.1097/QAD.0000000000001088
   PubMed Web of Science ®Google Scholar
• Auclair M, Afonso P, Capel E, Caron-Debarle M, Capeau J. Impact of darunavir, atazanavir and lopinavir boosted with ritonavir on cultured human endothelial cells: beneficial effect of pravastatin. Antivir Ther. 2014;19(8):773–782.10.3851/IMP2752
   PubMed Web of Science ®Google Scholar
• Jiang B, Khandelwal AR, Rogers LK, et al. Antiretrovirals induce endothelial dysfunction via an oxidant-dependent pathway and promote neointimal hyperplasia. Toxicol Sci. 2010;117(2):524–536.10.1093/toxsci/kfq213
   PubMed Web of Science ®Google Scholar
• Young J, Xiao Y, Moodie EE, et al. Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV cohort study. J Acquir Immune Defic Syndr. 2015;69(4):413–421.10.1097/QAI.0000000000000662
   PubMed Web of Science ®Google Scholar
• Sabin CA, Reiss P, Ryom L, et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration. BMC Med. 2016;14(1):1417.10.1186/s12916-016-0588-4
   Web of Science ®Google Scholar
• Tripathi A, Liese AD, Winniford MD, et al. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014;37(9):517–522.10.1002/clc.2014.37.issue-9
   PubMed Web of Science ®Google Scholar
• Fadini GP, Losordo D, Dimmeler S. Critical reevaluation of endothelial progenitor cell phenotypes for therapeutic and diagnostic use. Circ Res. 2012;110(4):624–637.10.1161/CIRCRESAHA.111.243386
   PubMed Web of Science ®Google Scholar